Release date: 16 April 2010
Promoter – Financial Intermediary
Bial Portela & CA SA.
Location
Description
The project concerns the R&D-activities in the period 2009 up to and including 2012, with a focus on drugs for epilepsy, cardiovascular affections and Parkinson’s disease. The project will take place at the company’s facilities mainly at Porto.
Objectives
Contribute to private sector investments in R&D.
Sector(s)
Proposed EIB finance (Approximate amount)
Up to EUR 50 million.
Total cost (Approximate amount)
Estimated at EUR 120 million.
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11; this will be verified during appraisal together with compliance of R&D activities with relevant EU legislation.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Status
Signed - 27/05/2010
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).